H.R. 8018In committeeHealth care
Bill would reclassify donor pancreatic islets as organs, not drugs
Data as of July 12, 2026
The ISLET Act would regulate donor pancreatic islets like transplant organs instead of drugs or biological products.35-second read · 4 questions answered below
Decoded
What does this do?
The ISLET Act would classify human islets from deceased donors the same way whole organs like kidneys are classified, rather than as drugs, biological products, or human tissue products. HHS would have one year to update related regulations and must report to Congress on progress within six months.
Who does it affect?
This affects patients needing islet transplants (often people with severe type 1 diabetes), transplant doctors and hospitals, organ procurement organizations, and companies that process islets.
Why does it matter?
The reclassification would shift islets out of drug/biological product regulatory pathways into organ transplant rules, changing which approval processes apply to their use.
Where does it stand?
- Introduced
- House committee — You are here
- House vote
- Senate
- President's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
AI-drafted summary. Verify it against the official text before you act on it.
Three steps: where you stand, your script, the call.
Make the callSee how a call works
Official title
ISLET Act
- Introduced:
- March 19, 2026
- Latest action:
- March 19, 2026
Referred to the House Committee on Energy and Commerce.
Read the official bill on Congress.govMake the call
Three steps: where you stand, your script, the call.